These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9473174)

  • 1. Peripheral blood progenitor cell transplantation: economic issues.
    Yee GC
    Pharmacotherapy; 1998; 18(1 Pt 2):9S-16S. PubMed ID: 9473174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced charges and costs associated with outpatient autologous stem cell transplantation.
    Meisenberg BR; Ferran K; Hollenbach K; Brehm T; Jollon J; Piro LD
    Bone Marrow Transplant; 1998 May; 21(9):927-32. PubMed ID: 9613786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
    Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
    Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Peripheral blood stem cell transplantation: current status and perspectives].
    Colombat P
    Bull Cancer; 1995; 82 Suppl 1():42s-48s. PubMed ID: 7542943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations.
    Gilbert CJ
    Pharmacotherapy; 1996; 16(3 Pt 2):101S-108S. PubMed ID: 8726589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy.
    Glaspy JA
    Bone Marrow Transplant; 1999 May; 23 Suppl 2():S21-7. PubMed ID: 10335873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic evaluation of blood stem-cells autologous transplantation].
    Corroller AG; Fortanier C; Faucher C; Blaise D; Moatti JP
    Bull Cancer; 2001 Sep; 88(9):893-9. PubMed ID: 11604363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
    Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
    Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood progenitor cell transplantation: impact on the pharmacy workload and budget.
    Davis TL
    Pharmacotherapy; 1998; 18(1 Pt 2):24S-29S. PubMed ID: 9473176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cells: enabling outpatient transplantation.
    McGuire TR; Tarantolo S; Reed E
    Pharmacotherapy; 1998; 18(1 Pt 2):17S-23S. PubMed ID: 9473175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
    De Rosa L; Lalle M; Pandolfi A; Pescador L
    Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient management strategies and transplantation techniques in european stem cell transplantation centers offering breast cancer patients high-dose chemotherapy with peripheral blood stem cell support: a joint report from the EORTC and EBMT.
    Neymark N; Rosti G
    Haematologica; 2000 Jul; 85(7):733-44. PubMed ID: 10897126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
    Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
    Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of peripheral blood progenitor cells as an autologous hematopoietic support in high-dose chemotherapy. I. The rationale and results].
    Silva MR; Passos-Coelho JL; da Costa FL; Machado MA; Miranda N; Miranda MH; Parreira A
    Acta Med Port; 1999; 12(7-11):265-73. PubMed ID: 10707464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of peripheral blood progenitor cells as an autologous hematopoietic support in high-dose chemotherapy. II. The experience of the Hematological Intensive Care Unit of the IPOFG. Franciso Gentil Portuguese Institute of Oncology].
    Silva MR; Passos-Coelho JL; da Costa FL; Machado MA; Miranda N; Miranda MH; Parreira A
    Acta Med Port; 1999; 12(7-11):275-81. PubMed ID: 10707465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation.
    Westerman IL; Bennett CL
    Stem Cells; 1996 May; 14(3):312-9. PubMed ID: 8724697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.